Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression

作     者：Basma M E Mohamed Mohamed E A Abdelrahim 

作者机构：Department of Clinical PharmacyFaculty of PharmacyBeni-Suef UniversityBeni-Suef 343433Egypt 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2024年第12卷第32期

页      面：6538-6542页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Idiopathic pulmonary fibrosis Pirfenidone Pirfenidone anti-inflammatory mechanism Pirfenidone antifibrotic activity Timing impact 

摘      要：In this editorial,we comment on the article by Lei et al,with a specific focus on the timing of the initiation of the antifibrotic agent pirfenidone(PFD)in the management of idiopathic pulmonary fibrosis(IPF)and its impact on lung function of IPF *** is an antifibrotic agent that is widely used in the management of IPF in both early and advanced *** inhibits various pathways and has antifibrotic,anti-inflammatory,and antioxidant *** dosage lowering,PFD slowed IPF progression and maintained functional *** 6-min walk distance test indicated that patients tolerated adverse events well,and PFD significantly reduced the incidence of progression episodes and *** when a single disease-progression event occurred,continuing PFD treatment had benefits.